NCT02674568

Who might be able to join this trial:

• You are 18 years of age or older
• You have been diagnosed with small cell lung cancer (SCLC) that has been confirmed by a tissue test, and your cancer has continued to grow or spread after at least 2 previous treatment regimens, including at least one that contained platinum-based chemotherapy
• Your tumor tissue has tested positive for a specific protein called DLL3, meaning it appears in at least 1% of your cancer cells, based on a lab test done on a tissue sample
• You have at least one area of cancer that can be measured on a scan, following standard medical guidelines (RECIST v1.1)
• You are generally able to carry out daily activities with little or no limitation (confirm with trial site regarding your specific activity level)
• Your doctor expects you to live for at least 12 weeks
• If your cancer has spread to the brain, it must have been stable or improving for at least 2 weeks after brain treatment, confirmed by a brain scan taken within 2 weeks before starting the study drug
• Any serious side effects from previous treatments have mostly cleared up before starting the study drug (with the exception of hair loss)
• Your blood counts and organ function (such as kidney and liver) are within acceptable ranges based on recent lab tests
• Enough time has passed since your last cancer treatment before starting this trial — the exact waiting period depends on the type of treatment you received (confirm with trial site for your specific situation)
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before your first dose of the study drug

Who may not be able to join:

• You have a serious uncontrolled medical condition, such as uncontrolled high blood pressure, uncontrolled diabetes, a serious lung condition that required a hospital stay in the last 6 months, or an active seizure disorder within the last 6 months
• You have had a stroke, mini-stroke (TIA), heart attack, unstable chest pain, or serious heart problems within the past 6 months
• You have or recently had a serious infection — for example, a severe viral, bacterial, or fungal infection within the last 2 weeks, HIV, or active hepatitis B or C
• You are currently breastfeeding
• You are taking high-dose steroid medications (more than 20 mg per day of prednisone or equivalent) within 1 week before starting the study drug
• You have had another type of cancer within the last 3 years (some exceptions may apply, such as certain skin cancers or early-stage cancers that were fully treated — confirm with trial site)
• You have previously been treated with a specific type of drug called a PBD-based drug, or you are known to be allergic to the study drug (rovalpituzumab tesirine) or any of its ingredients

Important: Always verify eligibility with the trial site directly before applying.